|
1 |
Hematology in times of crisis: lessons learned and strategic priorities from the EHA-ASH Joint Workshop on Ukraine
Istomin, Oleksandr. - Freiburg : Universität, 2026
|
|
|
|
2 |
Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia
Döhner, Hartmut. - Freiburg : Universität, 2026
|
|
|
|
3 |
Blauer Teil: Krankheitsbilder: Neoplastische Erkrankungen
Hochhaus, Andreas. - Stuttgart : Georg Thieme Verlag KG, 2025
|
|
|
|
4 |
Impact of myelodysplasia‐related and additional gene mutations in intensively treated patients with NPM1‐mutated AML
Cocciardi, Sibylle. - Freiburg : Universität, 2025
|
|
|
|
5 |
Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine
Bresser, Helena. - Augsburg : Universität Augsburg, 2025
|
|
|
|
6 |
Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia
Mecklenbrauck, Rabea. - Freiburg : Universität, 2025
|
|
|
7 |
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients
Enthalten in Leukemia 27.10.2025: 1-9
|
|
|
|
8 |
Effectiveness of venetoclax based therapy in t(11;14) multiple myeloma with extensive extramedullary disease: a case report
Enthalten in Annals of hematology 27.6.2025: 1-5
|
|
|
|
9 |
Progressive Multifocal Leukoencephalopathy (PML) after hematopoietic cell transplantation (HCT): a retrospective study of Infectious Diseases Working Party (IDWP) of the EBMT
Enthalten in Bone marrow transplantation 28.5.2025: 1-4
|
|
|
|
10 |
Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)
Rücker, Frank Gert. - Ulm : Universität Ulm, 2024
|
|
Administration
